Linda Laux
Pediatrics · Chicago, ILNPI 1912967951
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Biocodex, Inc. accounts for 87.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $13,537 and has fallen 87.4% since, to $1,710 in 2025. Among pediatrics clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $816.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocodex, Inc.$19K
- UCB, Inc.$2K
- Jazz Pharmaceuticals Inc.$361
- SK Life Science, Inc.$167
- Livanova USA, Inc.$144
- Sunovion Pharmaceuticals Inc.$123
- plus $145 from 3 others
Across 131 payments — averaging $5084.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$443K
- Takeda Pharmaceuticals U.S.A., Inc.$86K
- H. Lundbeck A S$82K
- Jazz Pharmaceuticals Inc.$30K
- Zogenix Inc.$26K
What the payments were for
- Consulting fees$11,78653%
- Speaking & faculty fees$7,98936%
- Travel & lodging$7183%
- Food & beverage$1,5477%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocodex, Inc. | 12 | $19,244 |
| UCB, Inc. | 4 | $1,873 |
| Jazz Pharmaceuticals Inc. | 3 | $361 |
| SK Life Science, Inc. | 2 | $167 |
| Livanova USA, Inc. | 1 | $144 |
| Sunovion Pharmaceuticals Inc. | 1 | $123 |
| Abbott | 1 | $83 |
| Nobelpharma America, LLC | 2 | $45 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DIACOMIT$19,061
- Fintepla$1,744
- Epidiolex$272
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$144
How this compares
$22,057 in reported general payments places this provider in the 95th percentile of 2,058 pediatrics providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 13 | $251,606 |
| EpidiolexCannabidiol (Cbd) | 18 | $33,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla | $1,873 | $251,60613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,058 pediatrics providers in Illinois.
Other pediatrics in Chicago
- Amy PallerChicago$1.2M
- Jan BergerChicago$886K
- Anita Chandra PuriChicago$367K
- Mindy SimpsonChicago$318K
- Anthony ManciniChicago$187K
- Patricia ChiamasChicago$155K
- Ruchi GuptaChicago$94K
- Emily SimmonsChicago$32K
- Theresa MottesChicago$25K
- Eliza ParkerChicago$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.